Formycon AG

Now free to read: In the two-part interview with Dave Wallace of #GenericsBulletin, Formycon CEO Dr. Stefan Glombitza talked about Formycon's strategy, recent development #milestones, an outlook for the coming months and the framework in biosimilar #development. https://lnkd.in/ePVH4AZf #TeamFormcon #Strategy #Biosimilars #Assets #Powerhouse #Biotech

𝐋𝐞𝐭'𝐬 𝐜𝐞𝐥𝐞𝐛𝐫𝐚𝐭𝐞 𝐖𝐨𝐫𝐥𝐝 𝐂𝐡𝐨𝐜𝐨𝐥𝐚𝐭𝐞 𝐃𝐚𝐲! Chocolate makes us happy, has a positive effect on stress and is even said to reduce the risk of a cardiac arrest. Reason enough to celebrate 𝐖𝐨𝐫𝐥𝐝 𝐂𝐡𝐨𝐜𝐨𝐥𝐚𝐭𝐞 𝐃𝐚𝐲 on July 7, marking the introduction of #chocolate to #Europe in 1550. However, the production of #cocoa is not entirely unproblematic due to the large amount of land required. In West Africa, where a large part of the world's cocoa production is based, large areas of tropical rainforest have already been sacrificed to cocoa cultivation, which is economically very important for the region. For Formycon, chocolate is therefore closely linked to the issue of #sustainability and reflects the #ESG project "Formycon Road to Sustainability". The #TeamFormycon chocolate bars of the fairly traded and climate-neutral "Gute Schokolade" from the "Plant for the Planet" foundation support reforestation projects and thus ensure that new trees are planted. Plus - it is really delicious!  

𝐅𝐨𝐫𝐦𝐲𝐜𝐨𝐧'𝐬 𝐣𝐨𝐮𝐫𝐧𝐞𝐲 𝐚𝐧𝐝 𝐥𝐚𝐭𝐞𝐬𝐭 𝐦𝐢𝐥𝐞𝐬𝐭𝐨𝐧𝐞 𝐡𝐚𝐯𝐞 𝐛𝐞𝐞𝐧 𝐡𝐢𝐠𝐡𝐥𝐢𝐠𝐡𝐭𝐞𝐝 𝐢𝐧 𝐖𝐢𝐫𝐭𝐬𝐜𝐡𝐚𝐟𝐭𝐬𝐖𝐨𝐜𝐡𝐞! "From their first big win in 1986 with Durachemie to building Hexal and investing in Biontech, the Strüngmann twins, Andreas and Thomas, have a proven track record. Now, their latest venture Hashtag #Formycon, has achieved #FDA approval for a biosimilar of the blockbuster eye medication #Eylea® (FYB203)." In the article by #WirtschaftWoche our #Formycon CEO Stefan Glombitza shares our ambitious plans, including a biosimilar for #Stelara® (FYB202) and the great potential of a #Keytruda® (FYB206) biosimilar. Dive into the full story of #WirtschaftsWoche here: https://lnkd.in/eEyiMV8a #biotech #pharma #innovation #healthcare #Formycon #StrüngmannTwins #WirtschaftsWoche #biosimilars

𝐄𝐲𝐥𝐞𝐚® 𝐛𝐢𝐨𝐬𝐢𝐦𝐢𝐥𝐚𝐫 𝐅𝐘𝐁𝟐𝟎𝟑 𝐚𝐩𝐩𝐫𝐨𝐯𝐞𝐝 𝐢𝐧 𝐔𝐒 With the US approval of #FYB203 (aflibercept) - after #FYB201 (ranibizumab) the second Formycon biosimilar for the treatment of severe retinal diseases - "we have established a strong position in #ophthalmic biosimilar therapies", comments Dr. Stefan Glombitza, CEO of Formycon AG. Wet, age-related macular degeneration and other diseases associated with severe visual impairment appear to be on the rise worldwide due to demographic trends. The Lucentis® biosimilar FYB201/Cimerli® has already been successfully established on the US market. With FYB203/AHZANTIVE®, the #FDA has now approved another effective and safe treatment option for these patients in the US. Read more in our Corporate News published today: https://lnkd.in/e6Ps5XWw   #TeamFormycon #Biosimilar #Martinsried #Bavaria #nAMD #Retina #US

𝐈𝐧𝐝𝐮𝐬𝐭𝐫𝐲-𝐬𝐩𝐞𝐜𝐢𝐟𝐢𝐜 𝐫𝐞𝐪𝐮𝐢𝐫𝐞𝐦𝐞𝐧𝐭𝐬 𝐟𝐨𝐫 𝐚 𝐝𝐢𝐠𝐢𝐭𝐚𝐥 𝐩𝐨𝐫𝐭𝐟𝐨𝐥𝐢𝐨 𝐚𝐧𝐝 𝐩𝐫𝐨𝐣𝐞𝐜𝐭 𝐦𝐚𝐧𝐚𝐠𝐞𝐦𝐞𝐧𝐭 𝐩𝐥𝐚𝐭𝐟𝐨𝐫𝐦 – 𝐅𝐨𝐫𝐦𝐲𝐜𝐨𝐧 𝐬𝐡𝐨𝐰𝐜𝐚𝐬𝐞𝐬 𝐢𝐧𝐧𝐨𝐯𝐚𝐭𝐢𝐯𝐞 𝐬𝐨𝐥𝐮𝐭𝐢𝐨𝐧𝐬 𝐚𝐭 𝐜𝐏𝐥𝐚𝐜𝐞 𝐏𝐡𝐚𝐫𝐦𝐚 𝐂𝐢𝐫𝐜𝐥𝐞.   During the event, customers showcase various business #solutions using #cPlace and discuss a range of topics, such as #AI, #regulatory requirements, and #cost #management. The aim is not only to facilitate the exchange of ideas among different pharmaceutical companies but also to clarify industry-specific requirements for the #software.   At the recent Pharma Circle held at Bayer in #Berlin, Beatrice Allwein and Jana Hasselbach presented Formycon's solution. The participants asked many intriguing questions, and the subsequent evening event led to highly productive discussions. Through this exchange with various pharmaceutical companies, we discovered that we all share a similar vision: implementing a digital solution as a single point of truth for collecting all relevant portfolio and project management data. The journey toward this goal presents both unique and common challenges in implementation.   #TeamFormycon #project #management #vision #exchange

Fierce Pharma Special Report: 𝐅𝐨𝐫𝐦𝐲𝐜𝐨𝐧 𝐝𝐞𝐯𝐞𝐥𝐨𝐩𝐬 𝐛𝐢𝐨𝐬𝐢𝐦𝐢𝐥𝐚𝐫 𝐜𝐚𝐧𝐝𝐢𝐝𝐚𝐭𝐞𝐬 𝐟𝐨𝐫 𝟑 𝐨𝐟 𝐭𝐡𝐞 𝐭𝐨𝐩 𝟐𝟎 𝐛𝐞𝐬𝐭-𝐬𝐞𝐥𝐥𝐢𝐧𝐠 𝐝𝐫𝐮𝐠𝐬 We are excited to announce that Formycon is developing biosimilar candidates for #Keytruda® (FYB206), #Stelara® (FYB202) and #Eylea® (FYB203) – 3 out of the top 20 best-selling drugs worldwide in 2023 listed in Fierce Pharma's recent report. According to Fierce, with $25 billion in global sales, front runner Keytruda® accounted for about 40% of Merck’s total revenue last year. Its sales are expected to reach $30 billion this year. Formycon recently announced the start of #clinical #development of its Keytruda® biosimilar candidate #FYB206. The report analyzes the pharmaceutical industry's leading products by sales, reflecting the significant demand for these medications globally. Our commitment to providing high-quality and affordable biosimilar products continues to drive our efforts in improving #patient #access to essential medications.   Check out the full #report here: https://lnkd.in/ea3RTE7t   #TeamFormycon #Biosimilars #Pharmaceuticals #TopDrugs2023

𝐅𝐨𝐫𝐦𝐲𝐜𝐨𝐧 𝐬𝐭𝐚𝐫𝐭𝐬 𝐜𝐥𝐢𝐧𝐢𝐜𝐚𝐥 𝐝𝐞𝐯𝐞𝐥𝐨𝐩𝐦𝐞𝐧𝐭 𝐩𝐫𝐨𝐠𝐫𝐚𝐦 𝐟𝐨𝐫 𝐅𝐘𝐁𝟐𝟎𝟔, 𝐚 𝐛𝐢𝐨𝐬𝐢𝐦𝐢𝐥𝐚𝐫 𝐜𝐚𝐧𝐝𝐢𝐝𝐚𝐭𝐞 𝐟𝐨𝐫 𝐢𝐦𝐦𝐮𝐧𝐨-𝐨𝐧𝐜𝐨𝐥𝐨𝐠𝐲 𝐛𝐥𝐨𝐜𝐤𝐛𝐮𝐬𝐭𝐞𝐫 𝐝𝐫𝐮𝐠 𝐊𝐞𝐲𝐭𝐫𝐮𝐝𝐚® (𝐏𝐞𝐦𝐛𝐫𝐨𝐥𝐢𝐳𝐮𝐦𝐚𝐛) “With the start of the clinical development program and the first patient in, we have reached a major #milestone. We are at the forefront of the development of a #pembrolizumab biosimilar. Our FYB206 project not only has immense commercial potential, but above all offers exceptional therapeutic options.”, commented Dr. Stefan Glombitza, CEO of Formycon AG. With the 𝐟𝐢𝐫𝐬𝐭 𝐩𝐚𝐭𝐢𝐞𝐧𝐭 𝐢𝐧 the Phase I clinical #trial, Formycon is among the first three biosimilar companies announcing entry into the #clinical #development phase for the #EU and #US market. For further #details, please check our corporate news published today: https://lnkd.in/eDBhBrUm #TeamFormycon #FYB206 #Biosimilar #PK #PD1 #Oncology

𝐄𝐯𝐞𝐫𝐲𝐭𝐡𝐢𝐧𝐠 𝐢𝐬 𝐰𝐞𝐥𝐥 𝐬𝐞𝐭: Today at 11:00 a.m., the Annual General Meeting of Formycon AG will be held at the Haus der bayerischen Wirtschaft in Munich. #TeamFormycon #Biosimilars #IR #AGM #HBW #Munich

𝐅𝐘𝐁𝟐𝟎𝟏 / 𝐑𝐚𝐯𝐞𝐠𝐳𝐚® 𝐥𝐚𝐮𝐧𝐜𝐡𝐞𝐝 𝐢𝐧 𝐒𝐚𝐮𝐝𝐢 𝐀𝐫𝐚𝐛𝐢𝐚   MS PHARMA, #FYB201 commercialization partner for the #MENA region, announced the FYB201 / Ravegza® launch in Saudi Arabia at a recent event with #retina #specialists from the region. Some great #impressions can be seen in the shared video.

We are returning from the Berenberg European Conference 2024 in #Manhattan with many positive impressions. The #conference was a great opportunity for us to talk about #biosimilars, our #growth #strategy and the dynamic development of the biosimilar #market. Many thanks to the Berenberg team for the great #organization and #hosting. #TeamFormycon #IR #Biosimilars #Development #Powerhouse